Although bevacizumab is known to increase bleeding risk, data presented from the IMbrave150 study do not show a clear trend regarding an increased risk of bleeding.
← all excerpts
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.
1
—
—